AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01530594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib/Lenalidomide/ Low dose Dex
Description: Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
Study NCT01530594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide/Low dose Dex (LLD
Study NCT02353052 — intervention group
Intervention type: OTHER
Intervention: follow up
Description: The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
Study NCT01150890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.
Study NCT01150890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.
Study NCT01303536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
Study NCT03340870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid™
Description: Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
Study NCT01747720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Given orally
Study NCT01747720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02243839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thrombolytic Therapy
Description: Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
Study NCT02243839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Redo valve surgery is performed for obstructive valve thrombosis
Study NCT01629966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
Study NCT01629966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 20mg, oral administration once per day.
Study NCT01629966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 40mg, oral administration once per day.
Study NCT02643017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
Study NCT02643017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
Study NCT01911663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KRG
Description: 500 mg Korea red ginseng (KRG)
Study NCT01911663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg placebo
Study NCT03771937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up intervention
Description: A telephone follow up and a pre-discharge education
Study NCT02006628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
Study NCT02006628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003
Description: GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
Study NCT01809483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bandage contact lens
Description: Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
Study NCT01809483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure patching
Description: Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
Study NCT02252783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFPET
Description: Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
Study NCT01849198 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: accelerometry m. trapezius and m. adductor pollicis
Study NCT01652209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hearticellgram-AMI
Study NCT02939430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex intravenous
Description: Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
Study NCT02939430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous neostigmine and atropine
Study NCT00702195 — intervention group
Intervention type: DRUG
Intervention: Org 36286 (corifollitropin alfa)
Description: single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
Study NCT00702195 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: single dose of placebo (administered under protocol 38805)
Study NCT00702195 — intervention group
Intervention type: DRUG
Intervention: recFSH
Description: 150 IU recFSH daily (reference group administered under protocol 38807)
Study NCT03159624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodesign™ SIS graft
Description: 2x3 cm Biodesign™ SIS perforated mesentery graft
Study NCT03159624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doyle silastic sheet
Description: Doyle silastic sheet
Study NCT03159624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doyle silastic sheet
Description: Doyle silastic sheet
Study NCT03906838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
Study NCT02044393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: multiple doses of itraconazole given as capsules
Study NCT02044393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: single dose BI 691751 given as tablet
Study NCT01086722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: karolinska cocktail
Description: The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol
Study NCT03940040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual Care
Study NCT03940040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen
Description: High flow nasal oxygen
Study NCT03133169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
Study NCT03133169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid regurge velocity
Description: Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
Study NCT03627494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study NCT01637935 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study NCT03164135 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CCR5 gene modification
Description: CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
Study NCT03064984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBS eyedrops
Description: CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
Study NCT03064984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PBS eyedrops
Description: PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
Study NCT02092831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 1
Study NCT02092831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 2
Study NCT02092831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose market image tablet of hardness 3
Study NCT02092831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single dose Phase 2 tablet formulation
Study NCT02545738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00804817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
Study NCT00804817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCION-HSCT program
Description: Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects.
Study NCT06338735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-High Frequency Ultrasound scan of minor salivary glands
Description: Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
Study NCT04219735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100mg BID
Study NCT04219735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT02624726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
Study NCT02624726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
Study NCT02624726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
Study NCT02624726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
Study NCT01320748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Processing
Description: A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
Study NCT01320748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention
Description: The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
Study NCT00136318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Study NCT00136318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00136318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
Study NCT00136318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
Study NCT00136318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
Study NCT00136318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
Study NCT00787579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifocal spectacles
Description: +1.50D bifocal spectacles
Study NCT00787579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prismatic bifocal spectacles
Description: +1.50D bifocal spectacles combined with 3Δ base-in prisms
Study NCT03670160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
Study NCT03670160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
Study NCT00577278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00577278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00577278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00577278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT00577278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO or IV
Study NCT00577278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo APBSCT
Study NCT00577278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV
Study NCT00577278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT03399669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
Study NCT01850511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibrissae trimming
Description: Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
Study NCT01850511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of oxymetazoline
Description: Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
Study NCT00967434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
Study NCT00967434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
Study NCT00967434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
Study NCT01348217 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node
Description: 40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
Study NCT01348217 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node
Description: 40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
Study NCT01348217 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Boost
Description: Boost 10 Gy in 5 fr, PTV = +1cm.
Study NCT01348217 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost
Description: Boost 26 Gy in 13 fr, PTV = +1cm.
Study NCT01348217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: FOLFOX 4
Description: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
Study NCT01348217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy: FOLFOX 4
Description: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
Study NCT02038569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel
Study NCT04187599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragon CRT®100 Contact Lens
Description: Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
Study NCT01255670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: penicillin and metronidazole in peritonsillar abscess
Description: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
Study NCT01255670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: penicillin and metronidazole in peritonsillar abscess
Description: Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
Study NCT04706052 — intervention group
Intervention type: OTHER
Intervention: Superficial Parotidectomy
Description: Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity